Abstract: Provided is a method for preventing the disturbance of vaginal bacterial flora during the menstrual period and improving the vaginal bacterial flora. One aspect of the present invention is a sanitary product carrying lactoferrin or a composition comprising lactoferrin and an auxiliary substance. Also provided is a kit comprising a sanitary product, and lactoferrin or the composition comprising lactoferrin and an auxiliary substance.

Abstract: The purpose of the present invention is to provide an agent for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora has been improved or normalized. An aspect of the present invention is an agent for improving intrauterine bacterial flora that contains lactoferrin or a salt thereof as an active ingredient. Additionally provided are: an agent or composition for improving intrauterine flora or treating or preventing diseases caused by the imbalance of intrauterine bacterial flora, the agent or composition containing lactoferrin or a salt thereof; a method for treating or preventing diseases caused by imbalance of intrauterine bacterial flora, the method comprising administrating the agent or composition; and a method for determining whether intrauterine bacterial flora has been improved or normalized.

Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or(Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.

Abstract: The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.

Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.

Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.

Abstract: An object of the present invention is to provide a novel drug inhibiting extracellular trap formation in leukocytes. The present invention provides an inhibitor of extracellular trap formation in leukocytes containing a lactoferrin fragment, and a composition containing lactoferrin for treating a disease related to the extracellular trap formation in leukocytes.

Abstract: A biologically active complex of lactoferrin with a branched non-peptide hydrophilic polymer, one example of which is represented by the following formula [1]: LF-[X-Lp-R—(Yp-POLY)q]n??[I] Wherein LF is lactoferrin, X is a linkage generated by reaction of functional groups, L is a linker, R is an aliphatic hydrocarbon group having at least 3 carbon atoms, Y is a heteroatom linkage, POLY is a non-peptide hydrophilic polymer, p is 0 or 1, q is an integer of 2 to 10, and n is an integer of 1 to 10.

Abstract: The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The composition of this invention is useful for treatment of at least one disease or condition selected from the group consisting of pains, including the phase 1 pain and the phase 2 pain, anxiety and stress. The composition is particularly beneficial to alleviating or getting rid of the pain and anxiety which significantly lower quality of life of patients with end-stage cancer. The composition of this invention is also useful for treatment of pains, including the phase 1 pain and the phase 2 pain, and inflammation which accompany arthritis or diseases in the junctions of bones (e.g. rheumatoid arthritis, osteoarthritis, frozen shoulder, sports injuries such as tennis elbow and baseball shoulder, and low back pain).

Abstract: A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a para-nitrophenol leaving group, under conditions that allow formation of an amide group between the PEG derivative and the lactoferrin. A PEGylated lactoferrin complex contains a linear PEG or a modified product thereof covalently bonded to lactoferrin via an amide bond, and a pharmaceutical composition includes a PEGlyated lactoferrin complex, a therapeutically inert base, and/or an additive.

Abstract: Ascochlorin or an analog or derivative thereof and a compound having a primary amino group are mixed and reacted with each other in the presence/absence of a basic catalyst to synthesize a novel imino compound. The novel imino compound thus synthesized is a ligand capable of activating nuclear receptor superfamily such as retinoid orphan receptor (RXR), peroxisome proliferator-activated receptor (PPAR) and steroid receptor (PXR), and shows an effect of promoting the transcription of a drug-metabolizing enzyme CYP7A1. The imino compound has a therapeutic effect on diseases such as lifestyle-related diseases, chronic inflammation and cancers.

Abstract: A biologically active complex of lactoferrin with a branched non-peptide hydrophilic polymer, one example of which is represented by the following formula [I]: LF-[X-Lp-R—(Yp-POLY)q]n ??[I] Wherein LF is lactoferrin, X is a linkage generated by reaction of functional groups, L is a linker, R is an aliphatic hydrocarbon group having at least 3 carbon atoms, Y is a heteroatom linkage, POLY is a non-peptide hydrophilic polymer, p is 0 or 1, q is an integer of 2 to 10, and n is an integer of 1 to 10.

Abstract: It is intended to provide a drug for ameliorating symptoms or diseases caused by heavy metals (for example, Wilson's disease, heavy metal toxication, aging, fulminant hepatitis and so on) which has a high safety without any fear of side effect, can eliminate heavy metals such as copper ion accumulated in excess in the living body to prevent or lessen the accumulation of the heavy metals in the living body, thereby eliminating or relieving the effects of the heavy metals; and compositions such as a medicinal composition, a food and a cosmetic containing the same. The drug and compositions as described above are characterized by containing lactoferrin and/or an active derivative of the same as the active ingredient.

Abstract: The present invention has an object to develop novel compounds which are effective for the therapy of syndrome X, cancer, myxedema, vascular chronic inflammation and the like, and furthermore prevent/treat the restenosis caused in an artery expansion by a balloon or a stent and have the activity facilitating regenerative medicine by inhibiting rejection of own cells or tissues to be transplanted and the method for preparing the same. Novel acetal derivatives obtained by acylating the hydroxyl group at the 2-position of the orcylaldehyde which ascochlorin and its analogs have and thereafter bonding an alcohol to the aldehyde group in the presence of a basic catalyst are found to achieve the object.

Abstract: The present invention has an object to develop novel compounds which are effective for the therapy of syndrome X, cancer, myxedema, vascular chronic inflammation and the like, and furthermore prevent/treat the restenosis caused in an artery expansion by a balloon or a stent and have the activity facilitating regenerative medicine by inhibiting rejection of own cells or tissues to be transplanted and the method for preparing the same. Novel acetal derivatives obtained by acylating the hydroxyl group at the 2-position of the orcylaldehyde which ascochlorin and its analogs have and thereafter bonding an alcohol to the aldehyde group in the presence of a basic catalyst are found to achieve the object.